# Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

> **NCT06245291** · PHASE2 · WITHDRAWN · sponsor: **Arbutus Biopharma Corporation**

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Imdusiran
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06245291
- **Lead sponsor:** Arbutus Biopharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245291, "Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06245291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*